<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tamoxifen: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tamoxifen: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tamoxifen: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9972" href="/d/html/9972.html" rel="external">see "Tamoxifen: Drug information"</a> and <a class="drug drug_patient" data-topicid="11068" href="/d/html/11068.html" rel="external">see "Tamoxifen: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709103"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Uterine malignancies and thromboembolic events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and life-threatening events from the use of tamoxifen include uterine malignancies, stroke, and pulmonary embolism. Fatal cases of each type of event have occurred.</p>
<p style="text-indent:-2em;margin-left:2em;">Incidence rates per 1,000 woman-years for these events were estimated from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial in women at high risk for breast cancer:</p>
<ul>
<li>
<p style="text-indent:0em;">Endometrial adenocarcinoma: 2.20 for tamoxifen versus 0.71 for placebo</p></li>
<li>
<p style="text-indent:0em;">Uterine sarcoma: 0.17 for tamoxifen versus 0.04 for placebo</p></li>
<li>
<p style="text-indent:0em;">Stroke: 1.43 for tamoxifen versus 1.00 for placebo.</p></li>
<li>
<p style="text-indent:0em;">Pulmonary embolism: 0.75 for tamoxifen versus 0.25 for placebo</p></li></ul>
<p style="text-indent:-2em;margin-left:2em;">Discuss the potential benefits of tamoxifen versus the potential risks of these serious events with women at high risk for breast cancer and women with ductal carcinoma in situ (DCIS) considering tamoxifen to reduce the risk of developing breast cancer. For most patients already diagnosed with breast cancer, the benefits of tamoxifen outweigh its risks.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F15512098"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Soltamox</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868326"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Tamox;</li>
<li>Nolvadex D [DSC];</li>
<li>TEVA-Tamoxifen</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1037302"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Estrogen Receptor Antagonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F224680"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3759a24-3dd1-40a1-bbb0-c041442ab870">Gynecomastia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gynecomastia: </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36389365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36389365'])">Ref</a></span>): Pubertal male Children ≥10 years and Adolescents: Oral: Usual dose: 10 to 20 mg twice daily; evaluate patient monthly to determine need for continued therapy. Reported duration of treatment is ≤9 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14719418','lexi-content-ref-15238910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14719418','lexi-content-ref-15238910'])">Ref</a></span>). Meta-analysis showed tamoxifen reduced breast size in 74% to 95% of patients, and a decrease of at least 50% was observed in 41% to 77.5% of patients; breast size reduction was observed 3 to 4 months after initiation of therapy and pain was resolved within 1 month of therapy in most patients; recurrence was noted in up to 14% of patients after discontinuing therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36389365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36389365'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c699c19b-0114-416d-b89f-9805c09eb18a">McCune-Albright syndrome; precocious puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>McCune-Albright syndrome; precocious puberty:</b> Limited data available: Female Children 2 to 10 years: Oral: 20 mg once daily; dosing based on a trial of 25 female patients ≤10 years of age (range: 2.9 to 10.9 years) who received treatment for 1 year; frequency of vaginal bleeding episodes was decreased; growth velocity was significantly decreased compared to pretreatment rates, as was skeletal maturation; ovarian and uterine volumes were increased; further studies are needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12915825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12915825'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a59aca1-079d-4bfb-96f5-5ed0b7a88433">Short stature</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Short stature: </b>Very limited data available: Pubertal male Adolescents: Oral: 10 to 20 mg twice daily with or without use of growth hormone therapy. Dosing based on small retrospective case series (n=7; age range: 13 to 16 years), which included subjects with primary diagnoses of idiopathic short stature, growth hormone deficiency, constitutional delay of growth and puberty, or neurosecretory growth hormone deficiency. Subjects received tamoxifen for a mean duration of 26 months (range: 6 to 48 months); patients experienced significantly decreased skeletal maturation rate and significantly increased predicted adult height; in all patients, secondary sexual development progressed normally (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16322179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16322179'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160330"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (not studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Chronic dialysis: No dosage adjustment necessary based on experience in adult patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23038759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23038759'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51160331"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; the effect of hepatic dysfunction on tamoxifen pharmacokinetics has not been determined.</p></div>
<div class="block doa drugH1Div" id="F224662"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9972" href="/d/html/9972.html" rel="external">see "Tamoxifen: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> For the treatment of breast cancer, patients receiving both tamoxifen and chemotherapy should receive treatment sequentially, with tamoxifen following completion of chemotherapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89d22de8-e4a8-41ee-83bc-1e4e83706316">Breast cancer, risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, risk reduction (pre- and postmenopausal high-risk females):</b>
<b>Oral:</b> 20 mg once daily for 5 years.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d96ea54-a23f-447d-bfb0-347ad995beca">Breast cancer, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant therapy:</i>
<b>Oral:</b> 20 mg once daily</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy:</i> Adjuvant therapy duration recommendations from American Society of Clinical Oncology (ASCO) guidelines:</p>
<p style="text-indent:-2em;margin-left:8em;">Pre- or perimenopausal at endocrine therapy initiation: Tamoxifen for an initial duration of 5 years; if pre- or perimenopausal (or status cannot be determined) after 5 years of therapy, may continue tamoxifen for a total duration of 10 years. If postmenopausal after 5 years of tamoxifen therapy, may continue tamoxifen for a total duration of 10 years, <b>or</b> switch to an aromatase inhibitor (AI) for up to a total duration of 10 years of endocrine therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30452337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30452337'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Postmenopausal at endocrine therapy initiation: Tamoxifen for a total duration of 10 years <b>or</b> tamoxifen for an initial duration of 5 years, followed by an AI for up to 5 years (for a total duration of 10 years of endocrine therapy) <b>or</b> tamoxifen for 2 to 3 years, followed by an AI for up to 5 years (for a total duration of 7 to 8 years of endocrine therapy) <b>or </b>an AI for 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30452337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30452337'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Male patients: ASCO guidelines for management of male breast cancer recommend an initial duration of 5 years. Five additional years of tamoxifen therapy may be offered if the initial 5 years of tamoxifen therapy are completed and tolerated and there is a high-risk of recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ductal carcinoma in situ (DCIS) (females), to reduce the risk for invasive breast cancer:</i>
<b>Oral: </b>20 mg once daily for 5 years.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Metastatic:</i>
<b>Oral: </b>20 mg once daily. Although the manufacturer's labeling recommends dosing of 20 to 40 mg daily (with doses &gt;20 mg administered in 2 divided doses), clinical benefit has not been demonstrated with doses above 20 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6380554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6380554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Guideline recommendations:</i> The American Society of Clinical Oncology (ASCO) guidelines for Endocrine Therapy for Hormone-Receptor Positive Metastatic Breast Cancer recommend the following based on menopausal status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34324367','lexi-content-ref-27217461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34324367','lexi-content-ref-27217461'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Premenopausal: Tamoxifen (in combination with ovarian suppression) may be offered as first-line therapy in patients with no prior endocrine therapy or in those who have received prior treatment with ovarian suppression and an AI; tamoxifen (with continued ovarian suppression) may also be offered as second-line therapy. Tamoxifen alone may be considered, but combination therapy is preferred.</p>
<p style="text-indent:-2em;margin-left:8em;">Postmenopausal: Tamoxifen may be offered as second-line therapy in patients with no prior endocrine therapy. In patients who have received prior endocrine therapy with tamoxifen, tamoxifen may be offered first- or second-line in patients with late relapse (&gt;12 months since adjuvant therapy). In patients who have received prior endocrine therapy with an AI, tamoxifen may be offered as first- or second-line therapy.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration of therapy:</i> Continue tamoxifen treatment until documented disease progression (documented by imaging, clinical examination, or disease-related symptoms).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80f60b6d-72a8-4adb-983b-17b69055d270">Endometrial carcinoma, recurrent, metastatic, or high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial carcinoma, recurrent, metastatic, or high-risk (endometrioid histologies only) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monotherapy:</i>
<b>Oral: </b>20 mg twice daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11208827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11208827'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy:</i>
<b>Oral: </b>20 mg twice daily for 3 weeks (alternating with megestrol acetate every 3 weeks); continue alternating until disease progression or unacceptable toxicity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14751131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14751131'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3759a24-3dd1-40a1-bbb0-c041442ab870">Gynecomastia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gynecomastia (off-label use):</b>
<b>Oral:</b> 20 mg once daily for up to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15681525','lexi-content-ref-17270340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15681525','lexi-content-ref-17270340'])">Ref</a></span>). The majority of published experiences have been in adult males with prostate cancer receiving bicalutamide. Use has also been reported in patients with idiopathic gynecomastia.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="79c914d3-8064-4065-a518-ee2d5c530015">Idiopathic male infertility</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Idiopathic male infertility (off label use): Oral:</b> 20 to 30 mg once daily for 3 to 6 months, then proceed to assisted reproductive therapy if pregnancy has not been achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23970453','lexi-content-ref-30134082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23970453','lexi-content-ref-30134082'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ef1953b-36a9-4c09-8890-ed7622c41621">Mastalgia, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mastalgia, severe (off-label use):</b>
<b>Oral:</b> 10 mg once daily for 3 months; may consider further treatment if relapse occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3052691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3052691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f299c321-7216-4b41-b8db-9549622ce036">Ovarian cancer, advanced and/or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced and/or recurrent (off-label use):</b>
<b>Oral:</b> 20 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2070324','lexi-content-ref-8690289']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2070324','lexi-content-ref-8690289'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1473d681-cecf-4aa4-9b27-de75ad3de13d">Ovulation induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovulation induction (in patients with breast cancer) (off-label use):</b>
<b>Oral:</b> 60 mg daily starting on the second or third day of the menstrual cycle (in combination with low-dose follicle-stimulating hormone [FSH]), and continued until the day of hCG administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15824416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15824416'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991940"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Chronic dialysis: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23038759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23038759'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989200"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F54438326"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hot flashes</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hot flashes</b> commonly occur and can drastically affect the quality of life in females taking tamoxifen. Because many females will take tamoxifen for more than 5 years for the treatment or prevention of breast cancer, the risk of nonadherence or discontinuation related to this condition should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20179808','lexi-content-ref-27583832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20179808','lexi-content-ref-27583832'])">Ref</a></span>). Females who associate tamoxifen treatment with hot flashes are 3 to 4 times more likely to report severe symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27583832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27583832'])">Ref</a></span>). Severity of symptoms decline during the last 2 years of treatment and within 3 to 6 months after tamoxifen therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27583832','lexi-content-ref-12085202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27583832','lexi-content-ref-12085202'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; exact mechanism unknown; thought to be due to antiestrogen effects in the CNS affecting the regulation of core body temperature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12480376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12480376'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; occurrence and severity increase over the first 3 months of therapy and remain consistent throughout therapy with highest rates (over 90%) in the first 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11899390','lexi-content-ref-27583832','lexi-content-ref-15494636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11899390','lexi-content-ref-27583832','lexi-content-ref-15494636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Premenopausal at diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018086'])">Ref</a></span>), younger age at menopause, history of naturally-occurring menopausal hot flashes prior to tamoxifen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20179808','lexi-content-ref-27583832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20179808','lexi-content-ref-27583832'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20179808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20179808'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking, caffeine, and alcohol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20179808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20179808'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression and anxiety (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27583832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27583832'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Being employed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27583832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27583832'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27583832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27583832'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ocular effects (including <b>corneal deposits</b>, <b>cataract</b>, <b>epithelial keratopathy, macular edema, maculopathy, optic neuritis, retinal thrombosis</b>, <b>retinopathy, </b>and<b> vision color changes</b>) have been reported in patients taking tamoxifen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26759403','lexi-content-ref-31169251','lexi-content-ref-21819259','lexi-content-ref-16974155','lexi-content-ref-8622006','lexi-content-ref-10707134','lexi-content-ref-14510798','lexi-content-ref-21119261','lexi-content-ref-22352823','lexi-content-ref-28882942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26759403','lexi-content-ref-31169251','lexi-content-ref-21819259','lexi-content-ref-16974155','lexi-content-ref-8622006','lexi-content-ref-10707134','lexi-content-ref-14510798','lexi-content-ref-21119261','lexi-content-ref-22352823','lexi-content-ref-28882942'])">Ref</a></span>). An increased need for cataract surgery has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21819259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21819259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose and time-related; retinal toxicity may occur due to axonal degeneration or a mechanism related to binding polar lipids resulting in drug-lipid accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14510798','lexi-content-ref-25606038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14510798','lexi-content-ref-25606038'])">Ref</a></span>). Chloride channel blockage in the lens has been proposed as the mechanism for cataract induction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21819259','lexi-content-ref-7929848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21819259','lexi-content-ref-7929848'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Variable; may occur at any time after tamoxifen initiation and may last after tamoxifen discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9775258','lexi-content-ref-10707134','lexi-content-ref-23448563','lexi-content-ref-10845279','lexi-content-ref-1591689','lexi-content-ref-21119261','lexi-content-ref-9373465','lexi-content-ref-26405621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9775258','lexi-content-ref-10707134','lexi-content-ref-23448563','lexi-content-ref-10845279','lexi-content-ref-1591689','lexi-content-ref-21119261','lexi-content-ref-9373465','lexi-content-ref-26405621'])">Ref</a></span>). Most reports are after 2 years of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21819259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21819259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk</i> factors:</p>
<p style="text-indent:-2em;margin-left:6em;">• Long duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10707134','lexi-content-ref-10845279','lexi-content-ref-24678744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10707134','lexi-content-ref-10845279','lexi-content-ref-24678744'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• While extremely high doses (240 to 320 mg/day) have been linked to ocular toxicity, doses ranging from 20 to 40 mg/day are also associated with visual function abnormalities and ocular effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21819259','lexi-content-ref-14510798','lexi-content-ref-8963159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21819259','lexi-content-ref-14510798','lexi-content-ref-8963159'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thromboembolic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and life-threatening thromboembolic events (some fatal) have occurred with tamoxifen, including <b>cerebrovascular accident </b>(stroke), <b>deep vein thrombosis </b>(DVT), and <b>pulmonary embolism </b>(PE). Risk normalized after discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21802721','lexi-content-ref-19569248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21802721','lexi-content-ref-19569248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; not clearly understood; proposed that estrogenic effects increase the risk. Influences anticoagulant proteins, such as antithrombin, protein S, and protein C similar to postmenopausal estrogen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8790074','lexi-content-ref-9663819','lexi-content-ref-9149031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8790074','lexi-content-ref-9663819','lexi-content-ref-9149031'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; PE events occurred at an average of 27 months after tamoxifen initiation (range: 2 to 60 months). DVT occurred at an average of 19 months (range: 2 to 57 months). Stroke occurred at an average of 30 months (range: 1 to 63 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Coadministration with chemotherapy</p>
<p style="text-indent:-2em;margin-left:6em;">• Doses ≥20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30973790','lexi-content-ref-9663819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30973790','lexi-content-ref-9663819'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;49 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16288118','lexi-content-ref-19569248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16288118','lexi-content-ref-19569248'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• First 24 months of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19569248','lexi-content-ref-22154240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19569248','lexi-content-ref-22154240'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High BMI (≥25 kg/m<sup>2</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16818854','lexi-content-ref-14512389','lexi-content-ref-9663819','lexi-content-ref-23835710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16818854','lexi-content-ref-14512389','lexi-content-ref-9663819','lexi-content-ref-23835710'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of surgery, fracture, and immobilization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14512389','lexi-content-ref-23835710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14512389','lexi-content-ref-23835710'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Factor V Leiden mutations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20554945','lexi-content-ref-9149031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20554945','lexi-content-ref-9149031'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14512389','lexi-content-ref-20554945','lexi-content-ref-19569248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14512389','lexi-content-ref-20554945','lexi-content-ref-19569248'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Personal history/family history of venous thromboembolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20554945','lexi-content-ref-19569248','lexi-content-ref-9663819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20554945','lexi-content-ref-19569248','lexi-content-ref-9663819'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Elevated blood pressure or cholesterol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19569248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19569248'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Uterine malignancies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Uterine malignancies have been reported with tamoxifen, including fatal cases of <b>endometrial carcinoma</b> and <b>uterine carcinoma (sarcoma).</b> The increased risk of endometrial cancer continues during therapy with tamoxifen but decreases after treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497694','lexi-content-ref-15894097','lexi-content-ref-29974455','lexi-content-ref-15741574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497694','lexi-content-ref-15894097','lexi-content-ref-29974455','lexi-content-ref-15741574'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; in uterine and endometrial tissue, the estrogenic effects of tamoxifen are associated with <b>endometrial polyp</b> formation, <b>endometrial hyperplasia</b>, and <b>uterine fibroids</b> which lead to increased risk of endometrial carcinoma and uterine sarcoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25788989','lexi-content-ref-18603495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25788989','lexi-content-ref-18603495'])">Ref</a></span>). Other mechanisms related to biomolecular pathways and signaling pathways have been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29974455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29974455'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; endometrial carcinoma has been reported as early as 6 months after initiation to 6 years after discontinuing tamoxifen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24563669','lexi-content-ref-8786205','lexi-content-ref-14709741','lexi-content-ref-16288118','lexi-content-ref-29974455','lexi-content-ref-9433432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24563669','lexi-content-ref-8786205','lexi-content-ref-14709741','lexi-content-ref-16288118','lexi-content-ref-29974455','lexi-content-ref-9433432'])">Ref</a></span>). Uterine sarcomas have been reported to develop a median of 6 to 9 years after initiation of tamoxifen, with a case developing 20 years after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12366669','lexi-content-ref-16343223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12366669','lexi-content-ref-16343223'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Cumulative dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10511593','lexi-content-ref-23219286','lexi-content-ref-29974455','lexi-content-ref-25788989','lexi-content-ref-18603495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10511593','lexi-content-ref-23219286','lexi-content-ref-29974455','lexi-content-ref-25788989','lexi-content-ref-18603495'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior estrogen replacement therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10511593','lexi-content-ref-18603495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10511593','lexi-content-ref-18603495'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10511593','lexi-content-ref-25788989','lexi-content-ref-18603495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10511593','lexi-content-ref-25788989','lexi-content-ref-18603495'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of endometrial abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29974455','lexi-content-ref-18603495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29974455','lexi-content-ref-18603495'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy of ≥2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11036892','lexi-content-ref-10511593','lexi-content-ref-11078487','lexi-content-ref-24563669','lexi-content-ref-23219286','lexi-content-ref-29974455','lexi-content-ref-22691381','lexi-content-ref-15741574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11036892','lexi-content-ref-10511593','lexi-content-ref-11078487','lexi-content-ref-24563669','lexi-content-ref-23219286','lexi-content-ref-29974455','lexi-content-ref-22691381','lexi-content-ref-15741574'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F224621"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (33%), hypertension (11%), peripheral edema (11%), vasodilation (41%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin changes (6% to 19%), skin rash (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (16%), fluid retention (32%), hot flash (19% to 80%)<span class="lexi-table-link-container"> (<a aria-label="Hot Flash table link" class="lexi-table-link" data-table-id="lexi-content-hot-flash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hot-flash')">table 1</a>)</span><span class="table-link" style="display:none;">Hot Flash</span>, weight loss (23%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hot Flash" frame="border" id="lexi-content-hot-flash" rules="all">
<caption style="text-align:center;">
<b>Tamoxifen: Adverse Reaction: Hot Flash</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Tamoxifen</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients </b></p>
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Tamoxifen</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cummings 1986</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">80%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">68%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Women at high risk for breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,681</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,707</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Soltamox PI 2019.06</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">64%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Women with axillary node-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,422</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,437</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Soltamox PI 2019.06</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (5% to 26%), nausea and vomiting (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Irregular menses (13% to 25%), vaginal discharge (12% to 55%), vaginal hemorrhage (6% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphedema (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (2% to 12%), fatigue, mood changes (12% to 18%), pain (3% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (11%), arthritis (14%), asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (5%), edema (4%), ischemic heart disease (3%), venous thromboembolism (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (5%), diaphoresis (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (3%), infrequent uterine bleeding (9%), menstrual disease (6%), ovarian cyst (3%), weight gain (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (1%), abdominal pain (9%), anorexia (1%), constipation (4% to 8%), diarrhea (7%), dyspepsia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Leukorrhea (9%), mastalgia (6%), urinary tract infection (10%), vaginitis (5%), vulvovaginitis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (5%), neoplasm (5%; second primary), thrombocytopenia (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (5%), increased serum bilirubin (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (6%), dizziness (8%), headache (8%), insomnia (9%), paresthesia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthropathy (5%), back pain (10%), bone fracture (7%; premenopausal increased risk) (Kyvernitakis 2018), musculoskeletal pain (3%), myalgia (5%), ostealgia (6%), osteoporosis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (8%)<span class="lexi-table-link-container"> (<a aria-label="Cataract table link" class="lexi-table-link" data-table-id="lexi-content-cataract" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cataract')">table 2</a>)</span><span class="table-link" style="display:none;">Cataract</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cataract" frame="border" id="lexi-content-cataract" rules="all">
<caption style="text-align:center;">
<b>Tamoxifen: Adverse Reaction: Cataract</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Tamoxifen</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients </b></p>
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Tamoxifen</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Women at high risk for breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,681</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,707</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (5%), cough (4% to 9%), dyspnea (8%), flu-like symptoms (6%), sinusitis (5%), throat irritation (oral solution: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Cyst (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cerebrovascular accident (Fisher 2005; Lai 2017), deep vein thrombosis<span class="lexi-table-link-container"> (<a aria-label="Deep Vein Thrombosis table link" class="lexi-table-link" data-table-id="lexi-content-deep-vein-thrombosis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-deep-vein-thrombosis')">table 3</a>)</span><span class="table-link" style="display:none;">Deep Vein Thrombosis</span>, pulmonary embolism<span class="lexi-table-link-container"> (<a aria-label="Pulmonary Embolism table link" class="lexi-table-link" data-table-id="lexi-content-pulmonary-embolism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pulmonary-embolism')">table 4</a>)</span><span class="table-link" style="display:none;">Pulmonary Embolism</span>, superficial thrombophlebitis</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Deep Vein Thrombosis" frame="border" id="lexi-content-deep-vein-thrombosis" rules="all">
<caption style="text-align:center;">
<b>Tamoxifen: Adverse Reaction: Deep Vein Thrombosis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Tamoxifen</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients </b></p>
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Tamoxifen</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Women at high risk for breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,681</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,707</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Women with axillary node-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,422</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,437</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pulmonary Embolism" frame="border" id="lexi-content-pulmonary-embolism" rules="all">
<caption style="text-align:center;">
<b>Tamoxifen: Adverse Reaction: Pulmonary Embolism</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Tamoxifen</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients </b></p>
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Tamoxifen</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.09%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Women at high risk for breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,681</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6,707</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Women with axillary node-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,422</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,437</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Endometrial carcinoma (Cohen 1996; Fisher 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic neoplasm</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Portal vein thrombosis (Hsu 2015), retinal thrombosis (Demirci 2019; Onder 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid, cutaneous lupus erythematosus (Andrew 2014), erythema multiforme, night sweats (Day 2001; Moon 2017), pruritus vulvae (Day 2001), Stevens-Johnson syndrome, toxic epidermal necrolysis (Madabhavi 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (Morales 2004; Mourits 2002), hypercalcemia (Legha 1981; Nikolic-Tomasevic 2001), hyperglycemia (Hozumi 1997; Kim 2014), hypertriglyceridemia (Liu 2003; Singh 2016), loss of libido (males) (Pemmaraju 2012; Wibowo 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis (Blackburn 1984), dysgeusia (Schiffman 2018), pancreatitis (Singh 2016; Tey 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dyspareunia (Mourits 2002), endometrial hyperplasia (Cheng 1997; Lindahl 2008), endometrial polyps (Cohen 1996; Neven 1998), endometriosis (Kraft 2006), impotence (Pemmaraju 2012), vaginal dryness (Mortimer 1999; Mourits 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Ching 1992; Herrscher 2020), leukopenia, malignant neoplasm of ovary (Cohen 1996; Ohara 2002), malignant neoplasm of uterus (Kloos 2002; Yildirim 2005), neutropenia (Herrscher 2020), pancytopenia (Mitani 2006), tumor flare (during treatment of metastatic breast cancer; generally resolves with continuation; includes increased lesion size and erythema) (Mulvenna 1999; Plotkin 1978), tumor lysis syndrome (Cech 1986), uterine carcinoma (sarcoma), uterine fibroids (Polin 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic necrosis (Ching 1992; Storen 2000), hepatitis (Oien 1999; Pinto 1995), liver steatosis (Roy 2019; Saphner 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Bork 2017; Rousset-Jablonski 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tumor pain (during treatment of metastatic breast cancer; generally resolves with continuation) (Mulvenna 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Subacute cutaneous lupus erythematosus (Andrew 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal deposits (Muftuoglu 2006; Tarafdar 2012), epithelial keratopathy (Noureddin 1999; Pavlidis 1992), macular edema (Murray 1998; Zafeiropoulos 2014), maculopathy (Bommireddy 2016; Srikantia 2010), optic neuritis (Colley 2004; Noureddin 1999), retinal hole without detachment (macula hole) (Cronin 2005), retinal pigment changes (Noureddin 1999), retinopathy (Georgalas 2013; Wang 2015), vision color changes (Eisner 2011; Salomao 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis (Kwon 2019), interstitial pneumonitis (Ahmed 2016), pulmonary fibrosis (Bentzen 1996), pulmonary injury (Etori 2017)</p></div>
<div class="block coi drugH1Div" id="F224637"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity (eg, angioedema, serious skin reactions) to tamoxifen or any component of the formulation; concurrent warfarin therapy or history of deep vein thrombosis or pulmonary embolism (when tamoxifen is used for breast cancer risk reduction in women at high risk for breast cancer or risk reduction of invasive breast cancer after treatment of ductal carcinoma in situ [DCIS]).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): History of stroke or at increased risk for developing endometrial cancer (when used in the prevention setting [not approved indication]); pregnancy.</p></div>
<div class="block war drugH1Div" id="F224618"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone mineral density: Tamoxifen use may be associated with changes in bone mineral density (BMD) and the effects may be dependent upon menstrual status. In postmenopausal patients, tamoxifen use is associated with a protective effect on BMD, preventing loss of BMD which lasts over the 5-year treatment period. In premenopausal patients, a decline (from baseline) in BMD mineral density has been observed in patients who continued to menstruate; may be associated with an increased risk of fractures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Hypercholesterolemia and postmarketing cases of hyperlipidemias have been reported. Periodic monitoring of cholesterol and triglycerides may be indicated in patients with preexisting hyperlipidemias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metastatic breast cancer: Local disease flare and increased bone and tumor pain may occur; may be associated with (good) tumor response; onset is shortly after therapy initiation and usually resolves rapidly. In some patients with bone metastasis, hypercalcemia has occurred, usually within a few weeks of therapy initiation. Institute appropriate hypercalcemia management; discontinue tamoxifen if hypercalcemia is severe.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Selective serotonin reuptake inhibitors (SSRI): Concomitant use with select SSRIs may result in decreased tamoxifen efficacy. Strong or moderate CYP2D6 inhibitors (eg, fluoxetine, paroxetine) are reported to interfere with transformation to the active metabolite endoxifen; when possible, select alternative medications with minimal or no impact on endoxifen levels (Sideras 2010). Weak CYP2D6 inhibitors (eg, venlafaxine, citalopram) have minimal effect on the conversion to endoxifen (Jin 2005); escitalopram is also a weak CYP2D6 inhibitor. In a retrospective analysis of breast cancer patients taking tamoxifen and SSRIs, concomitant use of paroxetine and tamoxifen was associated with an increased risk of death due to breast cancer (Kelly 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2D6 poor metabolizers: Lower plasma concentrations of endoxifen (active metabolite) have been observed in patients with reduced CYP2D6 activity (He 2021; Jin 2005; Schroth 2009) and may be associated with reduced efficacy, although data is conflicting. The routine use of CYP2D6 testing to identify patients not likely to benefit from tamoxifen is not supported (ASCO [Visvanathan 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878644"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>
<div class="block foc drugH1Div" id="F224631"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Soltamox: 10 mg/5 mL (150 mL) [sugar free; contains alcohol, usp, propylene glycol; licorice flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Soltamox: 10 mg/5 mL (150 mL [DSC]) [sugar free; contains alcohol, usp, propylene glycol; licorice-aniseed flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F224614"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F224640"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Soltamox Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $5.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tamoxifen Citrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $3.79</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868327"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nolvadex D: 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p></div>
<div class="block exp drugH1Div" id="F12807819"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;">A 0.5 mg/mL oral suspension may be prepared with tablets. Place two 10 mg tablets into 40 mL purified water and let stand ~2 to 5 minutes. Stir until tablets are completely disintegrated (dispersion time for each 10 mg tablet is ~2 to 5 minutes). Administer immediately after preparation. To ensure the full dose is administered, rinse glass several times with water and administer residue.</p>
<div class="reference">Lam MS, "Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs," <i>Pharmacotherapy</i>, 2011, 31(2):164-92.<span class="pubmed-id">21275495</span></div>
</div>
<div class="block admp drugH1Div" id="F52613896"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer tablets or oral solution with or without food; use supplied dosing cup for oral solution.</p></div>
<div class="block adm drugH1Div" id="F3878251"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer tablets or oral solution orally with or without food. Use supplied dosing cup for administration of oral solution.</p></div>
<div class="block hazard drugH1Div" id="F49132828"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F224651"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Do not freeze or refrigerate. Protect from light. Discard opened bottle after 3 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 20°C to 25°C (68°F to 77°F). Protect from light. Avoid excessive heat.</p></div>
<div class="block meg drugH1Div" id="F7874993"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication when used in females for breast cancer prevention or treatment of ductal carcinoma <i>in situ</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">Soltamox:<a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2005%2F021807lblMG.pdf&amp;token=WcvlQxgssOrvMr50LVn4VNy%2FBq0vk9FErwt7yVjly80cOcVLR9YH5QVCUHnycGy4zj%2BuBKAyz6NU7melXMbdvSXz0L27n9x6H0daRL5RERM%3D&amp;TOPIC_ID=87811" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021807lblMG.pdf</a></p></div>
<div class="block usep drugH1Div" id="F53568998"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of metastatic (female and male) breast cancer; adjuvant treatment of breast cancer after primary treatment with surgery and radiation; reduce risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) after surgery and radiation; reduce the incidence of breast cancer in women at high risk (all indications: FDA approved in adults); has also been used in treatment of precocious puberty associated with McCune-Albright syndrome in female children, short stature in pubertal males, and gynecomastia in pubertal males.</p></div>
<div class="block mst drugH1Div" id="F224713"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tamoxifen may be confused with pentoxifylline, raloxifene, Tambocor, tamsulosin, temazepam, toremifene</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F224698"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>
<div class="block dri drugH1Div" id="F224623"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anastrozole: Tamoxifen may decrease the serum concentration of Anastrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: Tamoxifen may enhance the adverse/toxic effect of Chloroquine. Specifically, concomitant use of tamoxifen and chloroquine may increase the risk of retinal toxicity. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. Management: Consider alternatives to the use of moderate CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with reduced clinical effectiveness of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. Management: Avoid concurrent use of strong CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with a reduced clinical effectiveness of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tamoxifen.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluoroestradiol F18: Estrogen Receptor Antagonists may diminish the diagnostic effect of Fluoroestradiol F18.  Management: Image patients with fluoroestradiol F-18 prior to starting systemic endocrine therapies that block the estrogen receptor. Use of fluoroestradiol F-18 should not delay indicated treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: Tamoxifen may enhance the adverse/toxic effect of Hydroxychloroquine. Specifically, concomitant use of tamoxifen and hydroxychloroquine may increase the risk of retinal toxicity. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letrozole: Tamoxifen may decrease the serum concentration of Letrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: Tamoxifen may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: May increase the serum concentration of Tamoxifen. Management: Concurrent use of ribociclib with tamoxifen is not indicated. Use of this combination may increase the effects and toxicities of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: CYP2C9 Inhibitors (Weak) may increase the serum concentration of TOLBUTamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Tamoxifen may increase the serum concentration of Vitamin K Antagonists.  Management: Use of a vitamin K antagonist (VKA) is contraindicated when tamoxifen is used to reduce breast cancer incidence and for ductal carcinoma in situ. Monitor VKA closely when tamoxifen is used to treat metastatic breast cancer or as adjuvant therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F224652"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice may decrease the metabolism of tamoxifen. Management: Monitor for increased effects/toxicity with concomitant use.</p></div>
<div class="block rep_considerations drugH1Div" id="F52062414"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant. Treatment should be initiated during menstruation or immediately after a negative pregnancy test.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective nonhormonal contraception or barrier contraceptives during tamoxifen therapy. Recommendations for how long contraception should continue once tamoxifen is discontinued vary. The US product labeling recommends contraception be continued for 2 months following the last tamoxifen dose; other sources suggest contraception be continued for 3 to 6 months (ESMO [Lambertini 2020]; ESMO [Peccatori 2013]) or longer (Nolvadex-D Canadian product monograph).</p>
<p style="text-indent:0em;margin-top:2em;">Tamoxifen may induce ovulation (Steiner 2005) or cause menstrual cycle irregularities. Based on animal data, tamoxifen may impair embryo implantation, but may not reliably cause infertility, even if menstrual cycles are irregular.</p>
<p style="text-indent:0em;margin-top:2em;">Use of tamoxifen has been considered for the treatment of idiopathic male infertility; however, benefits may be limited (ASRM [Schlegel 2021]; Colpi 2018).</p></div>
<div class="block pri drugH1Div" id="F224641"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to tamoxifen may cause fetal harm. However, available data are insufficient to establish a causal relationship; no pattern of birth defects has been observed, and the long-term effects of tamoxifen on development are not known (Braems 2011; Buonomo 2020; Schuurman 2019). There have been reports of vaginal bleeding, birth defects, spontaneous abortions and fetal death following use in pregnancy. Tamoxifen use during pregnancy may have a potential long-term risk to the fetus of a diethylstilbestrol (DES)-like syndrome (based on animal data).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). Use of tamoxifen during pregnancy may be contraindicated (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53568997"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">McCune-Albright syndrome: Females 2 to 10 years: In the pediatric clinical trial (study duration: 12 months), the following were monitored: Serum estradiol, estrone, dehydroepiandrosterone sulfate (DHEAS), luteinizing hormone, follicle-stimulating hormone, and insulin-like growth factor-1 (baseline and at 6 and 12 months of therapy); LFT (baseline and at 3, 6, and 12 months of therapy); CBC and INR at baseline; assessments of puberty status and growth at baseline and periodically during therapy (6 and 12 months): height, weight, Tanner stage, bone age (radiographs), vaginal bleeding data, and pelvic ultrasounds (Eugster 2003).</p>
<p style="text-indent:-2em;margin-left:2em;">Gynecomastia, short stature: Pubertal males ≥10 years: In pediatric trials, the following were monitored: CBC with platelets and LFT (baseline and monthly); testosterone, estrogen, luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone (baseline); growth parameters, and breast size (if applicable).</p></div>
<div class="block pha drugH1Div" id="F224617"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects; nonsteroidal agent with potent antiestrogenic properties which compete with estrogen for binding sites in breast and other tissues; cells accumulate in the G<sub>0</sub> and G<sub>1</sub> phases; therefore, tamoxifen is cytostatic rather than cytocidal.</p></div>
<div class="block phk drugH1Div" id="F224636"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely distributed to most tissues, particularly tissues that inhibit estrogen receptors (Perry 2012)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Highly protein bound (Perry 2012)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; via CYP2D6 to 4-hydroxytamoxifen and via CYP3A4/5 to N-desmethyl-tamoxifen. Each is then further metabolized into endoxifen (4-hydroxy-tamoxifen via CYP3A4/5 and N-desmethyl-tamoxifen via CYP2D6); both 4-hydroxy-tamoxifen and endoxifen are 30- to 100-fold more potent than tamoxifen</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tamoxifen oral solution is bioequivalent to tamoxifen tablets</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Tamoxifen: ~5 to 7 days; N-desmethyl tamoxifen: ~14 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 10 years (female): ~8 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: ~65% (primarily fecal); &lt;30% as unchanged drug and unconjugated metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Higher (~2.3-fold) in female pediatric patients (2 to 10 years) compared to adult breast cancer patients; within pediatric population, clearance faster in children 2 to 6 years compared to older children</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F224643"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ceadon | Crisafeno | Diemon | Farmifeno | Ginarsan | Nolvadex | Nolvadex d | Novaldex d | Tamofen | Tamoxifeno | Tamoxifeno Asofarm | Tamoxifeno biotenk | Tamoxifeno dosa | Tamoxifeno Eczane | Tamoxifeno filaxis | Tamoxifeno gador | Tamoxifeno Glenmark | Tamoxifeno gp pharm | Tamoxifeno lazar | Tamoxifeno r | Tamoxifeno sandoz | Tamoxifeno varifarma | Taxfeno | Trimetrox</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ebefen | Kessar | Nolvadex | Tamax | Tamoxifen | Tamoxifen arcana | Tamoxifen hexal | Tamoxifen ratiopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cm tamoxifen | Genox | Nolvadex | Nolvadex d | Tamosin | Tamoxen | Tamoxifen | Tamoxifen hexal | Tamoxifen-bc | Tw tamoxifen</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Novofen | Tamolex | Tamona | Tamoplex | Tamoxen | Zitazonium | Zymoplex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Doctamoxifene | Nolvadex | Nolvadex d | Novaldex d | Tamizam | Tamoplex | Tamoxifen bexal | Tamoxifen Ips | Tamoxifen merck-generics | Tamoxifen ratiopharm | Tamoxifen Sandoz | Tamoxifene eurogenerics</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamifen | Tamoxifen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bioxifeno | Citrato de tamoxifeno | Festone | Kessar | Nolvadex | Nolvadex d | Tacfen | Tamofen | Tamooex | Tamoplex | Tamoxifen | Tamoxin | Taxofen | Tecnotax</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Kessar | Nolvadex | Tamec | Tamoxifen | Tamoxifen Merck</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Kessar | Nolvadex | Prosanil | Tamolem | Tamoxifeno | Taxus</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamofen | Tamoxifen | Xi fen | Zitazonium</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Nolvadex d | Oncotamox | Tamoblas | Tamoplex | Tamoxifen | Tamoxifeno | Taxus</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Nolvadex d | Tamifen | Tamoplex | Tamoxifen | Zitazonium</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bonitam | Hormofem | Jenoxifen | Kessar | Mandofen | Nolvadex | Riboxifen | Tamobeta | Tamofen | Tamokadin | Tamopham | Tamox | Tamoxifen | Tamoxifen al | Tamoxifen aristo | Tamoxifen beta | Tamoxifen nc | Tamoxifen Saar | Tamoxifen-CT | Tamoxigenat | Tamoximerck | Tamoxistad | Tamoxiwieb | Zemide</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamoxifeno | Tamoxifran | Taxus</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Nolvadex d | Novofen | Tamoxifeno | Taxus</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamofen | Tamoxen | Tamoxifen | Tamoxifen ebewe | Zemide</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamodex | Tamofen | Tamoxifen | Tamoxin | Tamozonium | Zitazonium</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Oxeprax | Tamoxifeno bayvit | Tamoxifeno cinfa | Tamoxifeno edigen | Tamoxifeno elfar | Tamoxifeno ferrer | Tamoxifeno lepori | Tamoxifeno ratiopharm | Tamoxifeno sandoz | Tamoxifeno ur | Tamoxifeno vir</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Mamofen | Tamoxifen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ledertam | Nolven | Tadex | Tamcal | Tamexin | Tamofen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Kessar | Nolvadex | Oncotam | Tamofene | Tamoxifene actavis | Tamoxifene arrow | Tamoxifene Bayer | Tamoxifene Biogaran | Tamoxifene EG | Tamoxifene g gam | Tamoxifene gnr | Tamoxifene Merck | Tamoxifene ratiopharm | Tamoxifene rpg | Tamoxifene Sandoz | Tamoxifene teva | Tamoxifene Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Emblon | Fentamox | Kessar tamoxifen | Noltam | Nolvadex | Nolvadex d | Oestrifen | Tamofen | Tamoxifen | Tamoxifen aps | Tamoxifen arrow | Tamoxifen berk | Tamoxifen cox | Tamoxifen dup | Tamoxifen kent | Tamoxifen Sandoz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adifen | Defarol | Kessar | Nolvadex | Puretam | Tamoplex | Tamoxifen | Terimon | Zymoplex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo tamox | Nolvadex | Tamoplex | Tamoxifen | Tamoxifen ebewe | Tamoxifeno farmoz | Zitazonium</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamoxifen hexal | Tamoxifen-teva | Zitazonium</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tadex | Tamofen | Tamoplex | Tamoxifen | Tamoxifen ebewe | Taxen</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Nolgen | Nolvadex | Nolvadex d | Tamofen | Tamox | Tamoxifen</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Nolvadex d | Tamoplex | Tamoxen | Tamoxi</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Caditam | Camofen | Cytotam | Entax | Mamofen | Moxifen | Nolvadex | Oncomox | Oncotam | Tamodex | Tamoxifen | Tamoxilon | Tamtero | Tomifen | Xifen | Zutam</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kessar | Ledertam | Nolvadex | Nolvadex d | Nomafen | Tamoxene | Tamoxifene | Tamoxifene big | Tamoxifene EG | Tamoxifene pht | Tamoxifene ratiopharm</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Medo tamifen | Nolvadex | Novofen | Tamocit | Tamofen | Tamoxifen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Adopan | Elvax | Emalook | Nolvadex | Norxifen | Panleef | Phenolurn | Respol | Shosigen | Shosigen merck hoei | Siedelin | Soshigen | Tamofen | Tamoxifen | Tamoxifen Citrate Wyeth | Tamoxifen dsep | Tamoxifen mylan | Tasuomin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Nolvadex d | Tamoxifen</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kwangdong tamoxifen | Moxafen | Nolvadex | Nolvadex d | Tamoplex | Tamorex | Tamoxen | Tamoxifen | Tamoxifen hse</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Med-Tamoxifen | Nolvadex | Tamoxifen | Tamoxifen Sandoz | Tamoxifene | Tamoxit</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamifen | Tamofen | Tamoxifen | Tamoxifen al | Tamoxifen hexal | Tamoxifen mylan | Tamoxifen ratiopharm | Zitazonium</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamizam | Tamoxifen</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamifen | Tamofen | Tamoxifen | Tamoxifen hexal | Zitazonium</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tafen | Tamoxifene | Tamoxifene gt | Tamoxifene Merck</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bilem | Ezul | Femoxtal | Kessar | Nolvadex | Tamfenax | Tamoxifeno | Taxus | Tecnofen</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Genox | Nolvadex | Novafen | Novofen | Tamifen | Tamoplex | Tamoxifen | Zitazonium</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Annymoxifen | Tam | Tamilong | Tamoxifen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Nolvadex-20 | Nolvadex-40 | Tamoxifen | Tamoxifen ratiopharm</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamofen | Tamoxifen | Tamoxifen al | Tamoxifen Gea | Tamoxifen mylan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Genox | Nolvadex | Tamofen | Tamoxifen Sandoz</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ginarsan | Nolvadex | Nolvadex d | Tamoxifeno | Taxus</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biomedis tamoxifen | Canifen | Entax | Fenahex | Genzifen | Gynatam | Gyraxen | Kessar | Medtax | Mpl tamoxil | Nolvadex | Nolvadex d | Tamimex-20 | Tamoplex | Tamoxen | Tamoxsta | Xifen | Zitazonium</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cerotin | Medotamifen | Nolvadex | Tamofen | Tamooex | Tamoplex | Tamox | Tamoxical | Tamoxifen | Tamoxifeno | Temocab | Zitazonium | Zymoplex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Nolvadex d | Tamofen | Tamoxifen | Tamoxifen ebewe | Tamoxifen egis | Tamoxifen hexal | Zemide | Zitazonium</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamoxan | Tamoxifeno | Tamoxifeno tamoxan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Diemon | Tamoxifeno centro medico amanecer | Tamoxifeno cipla | Tamoxifeno d.a. carrion | Tamoxifeno dosa | Tamoxifeno gador | Tamoxifeno microsules | Tamoxifeno r | Tamoxifeno varifarma | Tamoxis | Taxfeno | Trimetrox | Zita</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Nolvadex-D | Tamophar</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Tamoxifen | Tamoxifen sopharma | Zitazonium</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bilem | Gen tamoxifen | Nolvadex | Novofen | Sinfen | Tamifen | Tamoplex | Tamoxifen | Tamoxifen Citrat | Tamoxifen ebewe | Tamoxifen ferein | Tamoxifen hexal | Tamoxifen lens | Tamoxifeni citras | Vero tamoxifen | Zitazonium</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo tamox | Nolvadex | Nolvadex d | Tamofen | Tamophar | Tamoplex | Tamoxifeno</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ledertam | Nolvadex | Tamofen | Tamoxifen | Tamoxifen ebb | Tamoxifen Gea | Tamoxifen Merck NM | Tamoxifen mylan | Tamoxifen Nordic Drugs | Tamoxifen Orifarm | Tamoxifen Sandoz</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo tamox | Nolvadex | Tamofen | Tamoxifen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Nolvadex d | Tamifen | Tamoplex | Tamoxifen | Zitazonium</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bilem | Gynatam | Mamofen | Moxafen | Nolvadex | Nolvadex d | Novofen | Onkofen | Tamodex | Tamofen | Tamoplex | Tamoxifen | Tamoxifen abic | Tamoxifen ebewe | Tamoxifen Sandoz | Tevafen | Tuosomin | Zitazonium</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ebefen | Nolvadex | Novofen | Tamifen | Tamofene | Tamoxifen | Zitazonium</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Apo tamox | Nolvadex | Nolvafen d | Tadex | Tamofen | Tamoplex | Tamoxifen | Tamoxifen-Cell | Tamoxifeno gador | Tamoxit | Zitazonium</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Defarol | Nolvadex | Novofen | Tadex | Tafen | Tamofen | Tamoplex | Tamoxifen | Taxifen</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Jenoxifen | Mamofen | Nolvadex | Tamoxen | Tamoxifen | Tamoxifenbene | Zitazonium</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamoxifen</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Crisafeno | Nolvadex | Tamoxifeno | Tennagen | Zita</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nolvadex | Tamoxifeno | Taxus</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Kessar | Neophedan | Nolvadex | Tamoxihexal</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cytotam | Mamofen | Nolvadex | Tamodex</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Neophedan 10</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16818854">
<a name="16818854"></a>Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N. Effect of factor V Leiden and prothrombin G20210--&gt;A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. <i>J Natl Cancer Inst</i>. 2006;98(13):904‐910. doi:10.1093/jnci/djj262<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/16818854/pubmed" id="16818854" target="_blank">16818854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9093207">
<a name="9093207"></a>Adamopoulos DA, Nicopoulou S, Kapolla N, Karamertzanis M, Andreou E. The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. <i>Fertil Steril</i>. 1997;67(4):756-762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9093207/pubmed" id="9093207" target="_blank">9093207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7672156">
<a name="7672156"></a>Adamopoulos DA, Nicopoulou S, Kapolla N, Vassilopoulos P, Karamertzanis M, Kontogeorgos L. Endocrine effects of testosterone undecanoate as a supplementary treatment to menopausal gonadotropins or tamoxifen citrate in idiopathic oligozoospermia. <i>Fertil Steril</i>. 1995;64(4):818-824.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/7672156/pubmed" id="7672156" target="_blank">7672156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14556812">
<a name="14556812"></a>Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. <i>Fertil Steril</i>. 2003;80(4):914-920. doi:10.1016/s0015-0282(03)01123-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/14556812/pubmed" id="14556812" target="_blank">14556812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ahmed.2009">
<a name="Ahmed.2009"></a>Ahmed S, Shahid RK. Acute interstitial pneumonitis following adjuvant tamoxifen therapy. <i>J Clin Oncol</i>. 2009;27(15 suppl):e11637-e11637.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3297810">
<a name="3297810"></a>AinMelk Y, Belisle S, Carmel M, Jean-Pierre T. Tamoxifen citrate therapy in male infertility. <i>Fertil Steril</i>. 1987;48(1):113-117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/3297810/pubmed" id="3297810" target="_blank">3297810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25292419">
<a name="25292419"></a>Andrew P, Valiani S, MacIsaac J, Mithoowani H, Verma S. Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review. <i>Breast Cancer Res Treat</i>. 2014;148(1):1-5. doi:10.1007/s10549-014-3150-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/25292419/pubmed" id="25292419" target="_blank">25292419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21848495">
<a name="21848495"></a>Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now?. <i>Climacteric</i>. 2011;14(5):515‐528. doi:10.3109/13697137.2011.608596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/21848495/pubmed" id="21848495" target="_blank">21848495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.<i> J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19469647">
<a name="19469647"></a>Behtash N, Hashemi R, Karimi Zarchi M. Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review. <i>Asian Pac J Cancer Prev</i>. 2009;10(1):163‐166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/19469647/pubmed" id="19469647" target="_blank">19469647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8656444">
<a name="8656444"></a>Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. <i>J Natl Cancer Inst</i>. 1996;88(13):918‐922. doi:10.1093/jnci/88.13.918<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/8656444/pubmed" id="8656444" target="_blank">8656444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36389365">
<a name="36389365"></a>Berger O, Landau Z, Talisman R. Gynecomastia: A systematic review of pharmacological treatments. <i>Front Pediatr</i>. 2022;10:978311. doi:10.3389/fped.2022.978311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/36389365/pubmed" id="36389365" target="_blank">36389365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11036892">
<a name="11036892"></a>Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. <i>Lancet</i>. 2000;356(9233):881‐887. doi:10.1016/s0140-6736(00)02677-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/11036892/pubmed" id="11036892" target="_blank">11036892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10511593">
<a name="10511593"></a>Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. <i>J Natl Cancer Inst</i>. 1999;91(19):1654‐1662. doi:10.1093/jnci/91.19.1654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/10511593/pubmed" id="10511593" target="_blank">10511593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6430441">
<a name="6430441"></a>Blackburn AM, Amiel SA, Millis RR, Rubens RD. Tamoxifen and liver damage. <i>Br Med J (Clin Res Ed)</i>. 1984;289(6440):288. doi:10.1136/bmj.289.6440.288<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/6430441/pubmed" id="6430441" target="_blank">6430441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15681525">
<a name="15681525"></a>Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. <i>J Clin Oncol</i>. 2005;23(4):808-815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/15681525/pubmed" id="15681525" target="_blank">15681525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26759403">
<a name="26759403"></a>Bommireddy T, Carrim ZI. To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity. <i>BMJ Case Rep</i>. 2016;2016:bcr2015213431. Published 2016 Jan 11. doi:10.1136/bcr-2015-213431<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/26759403/pubmed" id="26759403" target="_blank">26759403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11078487">
<a name="11078487"></a>Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study [published correction appears in J Clin Oncol. 2012 Jan 20;30(3):343]. <i>J Clin Oncol</i>. 2000;18(22):3748‐3757. doi:10.1200/JCO.2000.18.22.3748<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/11078487/pubmed" id="11078487" target="_blank">11078487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27878882">
<a name="27878882"></a>Bork K, Wulff K, Witzke G, Rietz S, Hardt J. Tamoxifen may cause life-threatening angioedema attacks in patients with hereditary angioedema. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(5):e237‐e239. doi:10.1111/jdv.14056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/27878882/pubmed" id="27878882" target="_blank">27878882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22020212">
<a name="22020212"></a>Braems G, Denys H, De Wever O, et al. Use of tamoxifen before and during pregnancy. <i>Oncologist</i>. 2011;16(11):1547-1551. doi: 10.1634/theoncologist.2011-0121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/22020212/pubmed" id="22020212" target="_blank">22020212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6380554">
<a name="6380554"></a>Bratherton DG, Brown CH, Bucha a R, et al, “A Comparison of Two Doses of Tamoxifen (Nolvadex) in Postmenopausal Women With Advanced Breast Cancer: 10 mg bd Versus 20 mg bd,” <i>Br J Cancer</i>, 1984, 50(2):199-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/6380554/pubmed" id="6380554" target="_blank">6380554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8373285">
<a name="8373285"></a>Breznik R, Borko E. Effectiveness of antiestrogens in infertile men. <i>Arch Androl</i>. 1993;31(1):43-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/8373285/pubmed" id="8373285" target="_blank">8373285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32398983">
<a name="32398983"></a>Buonomo B, Brunello A, Noli S, et al. Tamoxifen exposure during pregnancy: a systematic review and three more cases. <i>Breast Care (Basel)</i>. 2020;15(2):148-156. doi:10.1159/000501473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/32398983/pubmed" id="32398983" target="_blank">32398983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30452337">
<a name="30452337"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. <i>J Clin Oncol</i>. 2019;37(5):423-438. doi:10.1200/JCO.18.01160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/30452337/pubmed" id="30452337" target="_blank">30452337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34324367">
<a name="34324367"></a>Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(35):3959-3977. doi:10.1200/JCO.21.01392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/34324367/pubmed" id="34324367" target="_blank">34324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3331375">
<a name="3331375"></a>Buvat J, Buvat-Herbaut M, Marcolin G, Ardaens-Boulier K. Antiestrogens as treatment of female and male infertilities. <i>Horm Res</i>. 1987;28(2-4):219-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/3331375/pubmed" id="3331375" target="_blank">3331375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635348">
<a name="23635348"></a>Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. <i>Fertil Steril.</i> 2013;99(6):1476-1484. doi: 10.1016/j.fertnstert.2013.03.029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/23635348/pubmed" id="23635348" target="_blank">23635348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3014336">
<a name="3014336"></a>Cech P, Block JB, Cone LA, Stone R. Tumor lysis syndrome after tamoxifen flare. <i>N Engl J Med</i>. 1986;315(4):263‐264. doi:10.1056/NEJM198607243150417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/3014336/pubmed" id="3014336" target="_blank">3014336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24563669">
<a name="24563669"></a>Chen JY, Kuo SJ, Liaw YP, et al. Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study. <i>J Cancer</i>. 2014;5(2):151‐155. doi:10.7150/jca.8412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/24563669/pubmed" id="24563669" target="_blank">24563669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9264568">
<a name="9264568"></a>Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. <i>Gynecol Oncol</i>. 1997;66(2):233‐237. doi:10.1006/gyno.1997.4739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9264568/pubmed" id="9264568" target="_blank">9264568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1348345">
<a name="1348345"></a>Ching CK, Smith PG, Long RG. Tamoxifen-associated hepatocellular damage and agranulocytosis. <i>Lancet</i>. 1992;339(8798):940. doi:10.1016/0140-6736(92)90991-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/1348345/pubmed" id="1348345" target="_blank">1348345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23970453">
<a name="23970453"></a>Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. <i>Andrology</i>. 2013;1(5):749-757. doi: 10.1111/j.2047-2927.2013.00107.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/23970453/pubmed" id="23970453" target="_blank">23970453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8786205">
<a name="8786205"></a>Cohen I, Altaras MM, Shapira J, et al. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. <i>Int J Gynecol Pathol</i>. 1996;15(2):152‐157. doi:10.1097/00004347-199604000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/8786205/pubmed" id="8786205" target="_blank">8786205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14746604">
<a name="14746604"></a>Colley SM, Elston JS. Tamoxifen optic neuropathy. <i>Clin Exp Ophthalmol</i>. 2004;32(1):105‐106. doi:10.1046/j.1442-9071.2004.00769.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/14746604/pubmed" id="14746604" target="_blank">14746604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30134082">
<a name="30134082"></a>Colpi GM, Francavilla S, Haidl G, et al. European Academy of Andrology guideline management of oligo-astheno-teratozoospermia. <i>Andrology</i>. 2018;6(4):513-524. doi:10.1111/andr.12502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/30134082/pubmed" id="30134082" target="_blank">30134082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16983587">
<a name="16983587"></a>Cronin BG, Lekich CK, Bourke RD. Tamoxifen therapy conveys increased risk of developing a macular hole. <i>Int Ophthalmol</i>. 2005;26(3):101‐105. doi:10.1007/s10792-005-5424-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/16983587/pubmed" id="16983587" target="_blank">16983587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3534584">
<a name="3534584"></a>Cummings FJ, Gray R, Davis TE, et al. Tamoxifen versus placebo: double-blind adjuvant trial in elderly women with stage II breast cancer. <i>NCI Monogr</i>. 1986;(1):119-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/3534584/pubmed" id="3534584" target="_blank">3534584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14709741">
<a name="14709741"></a>Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. <i>J Natl Cancer Inst</i>. 2004;96(1):70‐74. doi:10.1093/jnci/djh007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/14709741/pubmed" id="14709741" target="_blank">14709741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497694">
<a name="25497694"></a>Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. <i>Lancet Oncol</i>. 2015;16(1):67‐75. doi:10.1016/S1470-2045(14)71171-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/25497694/pubmed" id="25497694" target="_blank">25497694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21802721">
<a name="21802721"></a>Davies C, Godwin J, Gray R; Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. <i>Lancet</i>. 2011;378(9793):771‐784. doi:10.1016/S0140-6736(11)60993-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/21802721/pubmed" id="21802721" target="_blank">21802721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23219286">
<a name="23219286"></a>Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet.</i> 2013;381(9869):805-816. doi:10.1016/S0140-6736(12)61963-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/23219286/pubmed" id="23219286" target="_blank">23219286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11795346">
<a name="11795346"></a>Day R; National Surgical Adjuvant Breast and Bowel Projet P-1 study (NSABP-1). Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. <i>Ann N Y Acad Sci</i>. 2001;949:143‐150.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/11795346/pubmed" id="11795346" target="_blank">11795346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30973790">
<a name="30973790"></a>DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. <i>J Clin Oncol</i>. 2019;37(19):1629‐1637. doi:10.1200/JCO.18.01779<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/30973790/pubmed" id="30973790" target="_blank">30973790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31169251">
<a name="31169251"></a>Demirci NS, Erdem GU, Uçgun Nİ, et al. A rare case: Branch retinal vein occlusion associated with the use of tamoxifen. <i>J Cancer Res Ther</i>. 2019;15(3):722‐724. doi:10.4103/0973-1482.204888<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/31169251/pubmed" id="31169251" target="_blank">31169251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14719418">
<a name="14719418"></a>Derman O, Kanbur NO, Kutluk T. Tamoxifen treatment for pubertal gynecomastia. <i>Int J Adolesc Med Health</i>. 2003;15(4):359-363. doi:10.1515/ijamh.2003.15.4.359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/14719418/pubmed" id="14719418" target="_blank">14719418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14512389">
<a name="14512389"></a>Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. <i>J Clin Oncol</i>. 2003;21(19):3588‐3593. doi:10.1200/JCO.2003.10.111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/14512389/pubmed" id="14512389" target="_blank">14512389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15894097">
<a name="15894097"></a>Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet</i>. 2005;365(9472):1687‐1717. doi:10.1016/S0140-6736(05)66544-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/15894097/pubmed" id="15894097" target="_blank">15894097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18309940">
<a name="18309940"></a>Eastell R, Adams JE, Coleman RE, et al, “Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230,” <i>J Clin Oncol</i>, 2008, 26(7):1051-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/18309940/pubmed" id="18309940" target="_blank">18309940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21819259">
<a name="21819259"></a>Eisner A, Luoh SW. Breast cancer medications and vision: effects of treatments for early-stage disease. <i>Curr Eye Res</i>. 2011;36(10):867‐885. doi:10.3109/02713683.2011.594202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/21819259/pubmed" id="21819259" target="_blank">21819259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28943550">
<a name="28943550"></a>Etori S, Nakano R, Kamada H, et al. Tamoxifen-induced lung injury. <i>Intern Med</i>. 2017;56(21):2903‐2906. doi:10.2169/internalmedicine.8649-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/28943550/pubmed" id="28943550" target="_blank">28943550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12915825">
<a name="12915825"></a>Eugster EA, Rubin SD, Reiter EO, et al, “Tamoxifen Treatment for Precocious Puberty in McCune-Albright Syndrome: A Multicenter Trial,” <i>J Pediatr</i>, 2003, 143(1):60-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/12915825/pubmed" id="12915825" target="_blank">12915825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3052691">
<a name="3052691"></a>Fentiman IS, Caleffi M, Hamed H, et al. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. <i>Br J Sur.</i> 1988;75(9):845-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/3052691/pubmed" id="3052691" target="_blank">3052691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14751131">
<a name="14751131"></a>Fiorica JV, Brunetto VL, Hanjani P, et al, “Phase II trial of Alternating Courses of Megestrol Acetate and Tamoxifen in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study,” <i>Gynecol Oncol</i>, 2004, 92(1):10-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/14751131/pubmed" id="14751131" target="_blank">14751131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16288118">
<a name="16288118"></a>Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. <i>J Natl Cancer Inst</i>. 2005;97(22):1652‐1662. doi:10.1093/jnci/dji372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/16288118/pubmed" id="16288118" target="_blank">16288118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29974455">
<a name="29974455"></a>Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. <i>Br J Surg</i>. 2018;105(9):1098‐1106. doi:10.1002/bjs.10899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/29974455/pubmed" id="29974455" target="_blank">29974455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17270340">
<a name="17270340"></a>Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. <i>Eur Urol</i>. 2007;52(1):106-114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/17270340/pubmed" id="17270340" target="_blank">17270340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21537036">
<a name="21537036"></a>Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older [published correction appears in <i>J Clin Oncol</i>. 2013 Nov 10;31(32):4167]. <i>J Clin Oncol</i>. 2011;29(17):2327‐2333. doi:10.1200/JCO.2010.33.0258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/21537036/pubmed" id="21537036" target="_blank">21537036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20554945">
<a name="20554945"></a>Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer [published correction appears in <i>J Natl Cancer Inst</i>. 2010 Aug 4;102(15):1210. Paskett, Electra M [corrected to Paskett, Electra D]]. <i>J Natl Cancer Inst</i>. 2010;102(13):942‐949. doi:10.1093/jnci/djq211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/20554945/pubmed" id="20554945" target="_blank">20554945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23630411">
<a name="23630411"></a>Georgalas I, Paraskevopoulos T, Papaconstaninou D, Brouzas D, Koutsandrea C. Large bilateral foveal cysts in the inner retina of a patient treated with tamoxifen, diagnosed with Fourier-domain optical coherence tomography. <i>Clin Ophthalmol</i>. 2013;7:707‐709. doi:10.2147/OPTH.S38951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/23630411/pubmed" id="23630411" target="_blank">23630411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17882159">
<a name="17882159"></a>Goetz MP, Kamal A, and Ames MM, “Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response,” <i>Clin Pharmacol Ther</i>, 2008, 83(1):160-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/17882159/pubmed" id="17882159" target="_blank">17882159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14745880">
<a name="14745880"></a>Hansmann A, Adolph C, Vogel T, et al, “High-Dose Tamoxifen and Sulindac as First-Line Treatment for Desmoid Tumors,” <i>Cancer</i>, 2004, 100(3):612-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/14745880/pubmed" id="14745880" target="_blank">14745880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058842">
<a name="32058842"></a>Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/32058842/pubmed" id="32058842" target="_blank">32058842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2070324">
<a name="2070324"></a>Hatch KD, Beecham JB, Blessing JA, et al, “Responsiveness of Patients With Advanced Ovarian Carcinoma to Tamoxifen. A Gynecologic Oncology Group Study of Second-Line Therapy in 10 Patients,” <i>Cancer</i>, 1991, 68(2):269-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/2070324/pubmed" id="2070324" target="_blank">2070324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34284099">
<a name="34284099"></a>He W, Eriksson M, Eliasson E, et al. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial. <i>Ann Oncol</i>. 2021;32(10):1286-1293. doi:10.1016/j.annonc.2021.07.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/34284099/pubmed" id="34284099" target="_blank">34284099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19569248">
<a name="19569248"></a>Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. <i>Cancer</i>. 2009;115(19):4442‐4449. doi:10.1002/cncr.24508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/19569248/pubmed" id="19569248" target="_blank">19569248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32231501">
<a name="32231501"></a>Herrscher H, Leblanc J, Petit T. Agranulocytosis induced by tamoxifen in a breast cancer patient. <i>Breast Care (Basel)</i>. 2020;15(1):72‐74. doi:10.1159/000500708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/32231501/pubmed" id="32231501" target="_blank">32231501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9466333">
<a name="9466333"></a>Hozumi Y, Kawano M, Miyata M. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. <i>Endocr J</i>. 1997;44(5):745‐749. doi:10.1507/endocrj.44.745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9466333/pubmed" id="9466333" target="_blank">9466333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26315359">
<a name="26315359"></a>Hsu A, Belkin E, Han S, Pellish R. Tamoxifen-associated portal vein thrombosis causing severe oesophageal variceal bleeding. <i>BMJ Case Rep</i>. 2015;2015:bcr2015209988. doi:10.1136/bcr-2015-209988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/26315359/pubmed" id="26315359" target="_blank">26315359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25788989">
<a name="25788989"></a>Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). <i>Oncol Lett</i>. 2015;9(4):1495‐1501. doi:10.3892/ol.2015.2962<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/25788989/pubmed" id="25788989" target="_blank">25788989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics committee on drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21775065">
<a name="21775065"></a>Iqbal J, Ginsburg OM, Wijeratne TD, et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. <i>Cancer Treat Rev</i>. 2012;38(4):318‐328. doi:10.1016/j.ctrv.2011.06.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/21775065/pubmed" id="21775065" target="_blank">21775065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23038759">
<a name="23038759"></a>Janus N, Launay-Vacher V, Thyss A, et al, “Management of Anticancer Treatment in Patients Under Chronic Dialysis: Results of the Multicentric CANDY (CANcer and DialYsis) Study,” <i>Ann Oncol</i>, 2013, 24(2):501-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/23038759/pubmed" id="23038759" target="_blank">23038759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15632378">
<a name="15632378"></a>Jin Y, Desta Z, Stearns V, et al, “CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment,” <i>J Natl Cancer Inst</i>, 2005, 97(1):30-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/15632378/pubmed" id="15632378" target="_blank">15632378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19018086">
<a name="19018086"></a>Jin Y, Hayes DF, Li L, et al. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. <i>J Clin Oncol</i>. 2008;26(36):5849‐5854. doi:10.1200/JCO.2008.16.8377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/19018086/pubmed" id="19018086" target="_blank">19018086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32516007">
<a name="32516007"></a>Johnson HM, Mitchell KB; Academy of Breastfeeding Medicine. ABM Clinical Protocol #34: Breast cancer and breastfeeding. <i>Breastfeed Med</i>. 2020;15(7):429-434. doi:10.1089/bfm.2020.29157.hmj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/32516007/pubmed" id="32516007" target="_blank">32516007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22691381">
<a name="22691381"></a>Jones ME, van Leeuwen FE, Hoogendoorn WE, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. <i>Breast Cancer Res</i>. 2012;14(3):R91. doi:10.1186/bcr3206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/22691381/pubmed" id="22691381" target="_blank">22691381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9576291">
<a name="9576291"></a>Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. <i>Cancer</i>. 1998;82(9):1698‐1703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9576291/pubmed" id="9576291" target="_blank">9576291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20142325">
<a name="20142325"></a>Kelly CM, Juurlink DN, Gomes T, et al, “Selective Serotonin Reuptake Inhibitors and Breast Cancer Mortality in Women Receiving Tamoxifen: A Population Based Cohort Study,” <i>BMJ</i>, 2010, 340:c693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/20142325/pubmed" id="20142325" target="_blank">20142325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25035662">
<a name="25035662"></a>Kim YA, Lee S, Jung JW, et al. Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia with diabetes mellitus. <i>Chin J Cancer Res</i>. 2014;26(3):341‐344. doi:10.3978/j.issn.1000-9604.2014.05.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/25035662/pubmed" id="25035662" target="_blank">25035662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20179808">
<a name="20179808"></a>Kligman L, Younus J. Management of hot flashes in women with breast cancer. <i>Curr Oncol</i>. 2010;17(1):81‐86. doi:10.3747/co.v17i1.473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/20179808/pubmed" id="20179808" target="_blank">20179808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12366669">
<a name="12366669"></a>Kloos I, Delaloge S, Pautier P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. <i>Int J Gynecol Cancer</i>. 2002;12(5):496‐500. doi:10.1046/j.1525-1438.2002.01134.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/12366669/pubmed" id="12366669" target="_blank">12366669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16439226">
<a name="16439226"></a>Kraft JK, Hughes T. Polypoid endometriosis and other benign gynaecological complications associated with Tamoxifen therapy-a case to illustrate features on magnetic resonance imaging. <i>Clin Radiol</i>. 2006;61(2):198‐201. doi:10.1016/j.crad.2005.09.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/16439226/pubmed" id="16439226" target="_blank">16439226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1544695">
<a name="1544695"></a>Krause W, Holland-Moritz H, Schramm P. Treatment of idiopathic oligozoospermia with tamoxifen—a randomized controlled study. <i>Int J Androl</i>. 1992;15(1):14-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/1544695/pubmed" id="1544695" target="_blank">1544695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16322179">
<a name="16322179"></a>Kreher NC, Eugster EA, Shankar RR. The use of tamoxifen to improve height potential in short pubertal boys. <i>Pediatrics</i>. 2005;116(6):1513-1515. doi:10.1542/peds.2005-0577<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/16322179/pubmed" id="16322179" target="_blank">16322179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31229774">
<a name="31229774"></a>Kwon E, Kim M, Choi E, Park Y, Kim C. Tamoxifen-induced acute eosinophilic pneumonia in a breast cancer patient. <i>Int J Surg Case Rep</i>. 2019;60:186‐190. doi:10.1016/j.ijscr.2019.02.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/31229774/pubmed" id="31229774" target="_blank">31229774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30032359">
<a name="30032359"></a>Kyvernitakis I, Kostev K, Hadji P. The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer. <i>Osteoporos Int</i>. 2018;29(11):2557-2564. doi:10.1007/s00198-018-4642-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/30032359/pubmed" id="30032359" target="_blank">30032359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29089895">
<a name="29089895"></a>Lai SW, Lin CL, Liao KF. Tamoxifen use correlates with increased risk of the first episode of ischemic cerebrovascular disease in older women with breast cancer: a case-control study in Taiwan. <i>Front Pharmacol</i>. 2017;8:742. doi:10.3389/fphar.2017.00742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/29089895/pubmed" id="29089895" target="_blank">29089895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32976936">
<a name="32976936"></a>Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. <i>Ann Oncol</i>. 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/32976936/pubmed" id="32976936" target="_blank">32976936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15238910">
<a name="15238910"></a>Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. <i>J Pediatr</i>. 2004;145(1):71-76. doi:10.1016/j.jpeds.2004.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/15238910/pubmed" id="15238910" target="_blank">15238910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7260871">
<a name="7260871"></a>Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. <i>Cancer</i>. 1981;47(12):2803‐2806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/7260871/pubmed" id="7260871" target="_blank">7260871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18505063">
<a name="18505063"></a>Lindahl B, Andolf E, Ingvar C, Ranstam J, Willén R. Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma. <i>Anticancer Res</i>. 2008;28(2B):1259‐1262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/18505063/pubmed" id="18505063" target="_blank">18505063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12779077">
<a name="12779077"></a>Liu CL, Yang TL. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. <i>Breast Cancer Res Treat</i>. 2003;79(1):11‐16. doi:10.1023/a:1023348021773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/12779077/pubmed" id="12779077" target="_blank">12779077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11899390">
<a name="11899390"></a>Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK. Tamoxifen-induced hot flashes. <i>Clin Breast Cancer</i>. 2000;1(1):52‐56. doi:10.3816/cbc.2000.n.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/11899390/pubmed" id="11899390" target="_blank">11899390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).<i> Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25878231">
<a name="25878231"></a>Madabhavi I, Revannasiddaiah S, Patel A, Anand A. Toxic epidermal necrolysis with the use of tamoxifen. <i>BMJ Case Rep</i>. 2015;2015:bcr2014209102. doi:10.1136/bcr-2014-209102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/25878231/pubmed" id="25878231" target="_blank">25878231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8790074">
<a name="8790074"></a>Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. <i>Arch Intern Med</i>. 1996;156(16):1806‐1810.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/8790074/pubmed" id="8790074" target="_blank">8790074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8690289">
<a name="8690289"></a>Markman M, Iseminger KA, Hatch KD, et al, “Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report,” <i>Gynecol Oncol</i>, 1996, 62(1):4-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/8690289/pubmed" id="8690289" target="_blank">8690289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9663819">
<a name="9663819"></a>Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. <i>Br J Clin Pharmacol</i>. 1998;45(6):608‐612. doi:10.1046/j.1365-2125.1998.00733.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9663819/pubmed" id="9663819" target="_blank">9663819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16770108">
<a name="16770108"></a>Mitani N, Sakuragi S, Matsuda K, Tanaka Y, Matsui K, Shinohara K. A breast cancer patient with myelodysplastic syndrome postoperatively treated by radiation and tamoxifen administration--a case report. <i>Gan To Kagaku Ryoho</i>. 2006;33(6):833‐836.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/16770108/pubmed" id="16770108" target="_blank">16770108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583832">
<a name="27583832"></a>Moon Z, Hunter MS, Moss-Morris R, Hughes LD. Factors related to the experience of menopausal symptoms in women prescribed tamoxifen. <i>J Psychosom Obstet Gynaecol</i>. 2017;38(3):226‐235. doi:10.1080/0167482X.2016.1216963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/27583832/pubmed" id="27583832" target="_blank">27583832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494636">
<a name="15494636"></a>Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. <i>Anticancer Drugs</i>. 2004;15(8):753‐760. doi:10.1097/00001813-200409000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/15494636/pubmed" id="15494636" target="_blank">15494636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10334535">
<a name="10334535"></a>Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. <i>J Clin Oncol</i>. 1999;17(5):1488‐1492. doi:10.1200/JCO.1999.17.5.1488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/10334535/pubmed" id="10334535" target="_blank">10334535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12085202">
<a name="12085202"></a>Mourits MJ, Böckermann I, de Vries EG, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. <i>Br J Cancer</i>. 2002;86(10):1546‐1550. doi:10.1038/sj.bjc.6600294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/12085202/pubmed" id="12085202" target="_blank">12085202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16974155">
<a name="16974155"></a>Muftuoglu O, Uçakhan OO, Kanpolat A. Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate. <i>Eye Contact Lens</i>. 2006;32(5):228‐232. doi:10.1097/01.icl.0000201396.74294.85<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/16974155/pubmed" id="16974155" target="_blank">16974155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10465476">
<a name="10465476"></a>Mulvenna PM, Wright AJ, Podd TJ. Life-threatening tamoxifen-induced hypercalcaemia. <i>Clin Oncol (R Coll Radiol)</i>. 1999;11(3):193‐195. doi:10.1053/clon.1999.9041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/10465476/pubmed" id="10465476" target="_blank">10465476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9775258">
<a name="9775258"></a>Murray DC, Gibson JM. Retinal changes associated with tamoxifen treatment for breast cancer. <i>Eye (Lond)</i>. 1998;12(pt 3a):485‐486. doi:10.1038/eye.1998.114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9775258/pubmed" id="9775258" target="_blank">9775258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8622006">
<a name="8622006"></a>Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. <i>J Clin Oncol</i>. 1996;14(3):1018‐1026. doi:10.1200/JCO.1996.14.3.1018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/8622006/pubmed" id="8622006" target="_blank">8622006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9433432">
<a name="9433432"></a>Neven P, De Muylder X, Van Belle Y, Van Hooff I, Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. <i>Lancet</i>. 1998;351(9095):36. doi:10.1016/s0140-6736(05)78091-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9433432/pubmed" id="9433432" target="_blank">9433432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11244326">
<a name="11244326"></a>Nikolic-Tomasević Z, Jelic S, Popov I, Radosavljević D, Mitrović L. Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates? <i>Oncology</i>. 2001;60(2):123‐126. doi:10.1159/000055308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/11244326/pubmed" id="11244326" target="_blank">11244326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11244326">
<a name="11244326"></a>Nolvadex-D (tamoxifen) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/11244326/pubmed" id="11244326" target="_blank">11244326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10707134">
<a name="10707134"></a>Noureddin BN, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A. Ocular toxicity in low-dose tamoxifen: a prospective study. <i>Eye (Lond)</i>. 1999;13 ( Pt 6):729‐733. doi:10.1038/eye.1999.217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/10707134/pubmed" id="10707134" target="_blank">10707134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12521448">
<a name="12521448"></a>Ohara N, Kobayashi A. Two case reports of ovarian cancer after long-term tamoxifen treatment for breast cancer. <i>J Obstet Gynaecol</i>. 2002;22(5):572‐573. doi:10.1080/014436102760299015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/12521448/pubmed" id="12521448" target="_blank">12521448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10023952">
<a name="10023952"></a>Oien KA, Moffat D, Curry GW, et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. <i>Lancet</i>. 1999;353(9146):36‐37. doi:10.1016/S0140-6736(05)74872-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/10023952/pubmed" id="10023952" target="_blank">10023952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15824416">
<a name="15824416"></a>Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. <i>J Clin Oncol.</i> 2005;23(19):4347-4353. doi:10.1200/JCO.2005.05.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/15824416/pubmed" id="15824416" target="_blank">15824416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30630643">
<a name="30630643"></a>Omar MI, Pal RP, Kelly BD, et al. Benefits of empiric nutritional and medical therapy for semen parameters and pregnancy and live birth rates in couples with idiopathic infertility: a systematic review and meta-analysis. <i>Eur Urol.</i> 2019;75(4):615-625. doi: 10.1016/j.eururo.2018.12.022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/30630643/pubmed" id="30630643" target="_blank">30630643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23448563">
<a name="23448563"></a>Onder Hİ, Kilic AC, Kose SA, et al. Branch retinal vein occlusion associated with tamoxifen use. <i>Semin Ophthalmol</i>. 2013;28(2):88‐90. doi:10.3109/08820538.2012.760618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/23448563/pubmed" id="23448563" target="_blank">23448563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22154240">
<a name="22154240"></a>Onitilo AA, Doi SA, Engel JM, Glurich I, Johnson J, Berg R. Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. <i>Thromb Res</i>. 2012;130(1):27‐31. doi:10.1016/j.thromres.2011.11.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/22154240/pubmed" id="22154240" target="_blank">22154240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10845279">
<a name="10845279"></a>Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. <i>Breast Cancer Res Treat</i>. 2000;60(2):167‐172. doi:10.1023/a:1006342300291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/10845279/pubmed" id="10845279" target="_blank">10845279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14510798">
<a name="14510798"></a>Parkkari M, Paakkala AM, Salminen L, Holli K; Finnish Breast Cancer Group. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. <i>Acta Ophthalmol Scand</i>. 2003;81(5):495‐499. doi:10.1034/j.1600-0420.2003.00116.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/14510798/pubmed" id="14510798" target="_blank">14510798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1591689">
<a name="1591689"></a>Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. <i>Cancer</i>. 1992;69(12):2961‐2964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/1591689/pubmed" id="1591689" target="_blank">1591689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33115771">
<a name="33115771"></a>Peccatori FA, Codacci-Pisanelli G, Mellgren G, et al. First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study. <i>ESMO Open</i>. 2020;5(5):e000859. doi:10.1136/esmoopen-2020-000859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/33115771/pubmed" id="33115771" target="_blank">33115771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22085764">
<a name="22085764"></a>Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. <i>Ann Oncol</i>. 2012;23(6):1471‐1474. doi:10.1093/annonc/mdr459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/22085764/pubmed" id="22085764" target="_blank">22085764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15863377">
<a name="15863377"></a>Perdoná S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. <i>Lancet Oncol</i>. 2005;6(5):295-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/15863377/pubmed" id="15863377" target="_blank">15863377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perry.2012">
<a name="Perry.2012"></a>Perry MC, ed. Chemotherapeutic agents: tamoxifen. In: <i>The Chemotherapy Source Book</i>. 5th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8530816">
<a name="8530816"></a>Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis--report of three cases. <i>J Hepatol</i>. 1995;23(1):95‐97. doi:10.1016/0168-8278(95)80316-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/8530816/pubmed" id="8530816" target="_blank">8530816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-712982">
<a name="712982"></a>Plotkin D, Lechner JJ, Jung WE, Rosen PJ. Tamoxifen flare in advanced breast cancer. <i>JAMA</i>. 1978;240(24):2644‐2646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/712982/pubmed" id="712982" target="_blank">712982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18603495">
<a name="18603495"></a>Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. <i>Cancer Imaging</i>. 2008;8(1):135‐145. doi:10.1102/1470-7330.2008.0020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/18603495/pubmed" id="18603495" target="_blank">18603495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19482875">
<a name="19482875"></a>Rousset-Jablonski C, Thalabard JC, Gompel A. Tamoxifen contraindicated in women with hereditary angioedema? <i>Ann Oncol</i>. 2009;20(7):1281‐1282. doi:10.1093/annonc/mdp295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/19482875/pubmed" id="19482875" target="_blank">19482875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31807482">
<a name="31807482"></a>Roy S, Ghosh J, Shetty N, Menon MB, Ramaswamy A, Gupta S. Tamoxifen and fulvestrant induced steatohepatitis with cirrhosis: A rare case report. <i>South Asian J Cancer</i>. 2019;8(4):225. doi:10.4103/sajc.sajc_132_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/31807482/pubmed" id="31807482" target="_blank">31807482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27217461">
<a name="27217461"></a>Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. <i>J Clin Oncol</i>. 2016;34(25):3069-3103. doi: 10.1200/JCO.2016.67.1487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/27217461/pubmed" id="27217461" target="_blank">27217461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17453956">
<a name="17453956"></a>Salomão SR, Watanabe SE, Berezovsky A, Motono M. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. <i>Curr Eye Res</i>. 2007;32(4):345‐352. doi:10.1080/02713680701229638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/17453956/pubmed" id="17453956" target="_blank">17453956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19484789">
<a name="19484789"></a>Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. <i>Cancer</i>. 2009;115(14):3189‐3195. doi:10.1002/cncr.24374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/19484789/pubmed" id="19484789" target="_blank">19484789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30035266">
<a name="30035266"></a>Schiffman SS. Influence of medications on taste and smell. <i>World J Otorhinolaryngol Head Neck Surg</i>. 2018;4(1):84‐91. doi:10.1016/j.wjorl.2018.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/30035266/pubmed" id="30035266" target="_blank">30035266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33309061">
<a name="33309061"></a>Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II. <i>Fertil Steril</i>. 2021;115(1):62-69. doi:10.1016/j.fertnstert.2020.11.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/33309061/pubmed" id="33309061" target="_blank">33309061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19809024">
<a name="19809024"></a>Schroth W, Goetz MP, Hamann U, et al, “Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen,” <i>JAMA,</i> 2009, 302(13):1429-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/19809024/pubmed" id="19809024" target="_blank">19809024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30707336">
<a name="30707336"></a>Schuurman TN, Witteveen PO, van der Wall E, et al. Tamoxifen and pregnancy: an absolute contraindication? <i>Breast Cancer Res Treat.</i> 2019. doi: 10.1007/s10549-019-05154-7. [Epub ahead of print].<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/30707336/pubmed" id="30707336" target="_blank">30707336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22502790">
<a name="22502790"></a>Serretta V, Altieri V, Morgia G, et al. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. <i>Clin Genitourin Cancer</i>. 2012;10(3):174-179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/22502790/pubmed" id="22502790" target="_blank">22502790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20439629">
<a name="20439629"></a>Sideras K, Ingle JN, Ames MM, et al, “Coprescription of Tamoxifen and Medications That Inhibit CYP2D6,” <i>J Clin Oncol</i>, 2010, 28(16):2768-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/20439629/pubmed" id="20439629" target="_blank">20439629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27127396">
<a name="27127396"></a>Singh HK, Prasad MS, Kandasamy AK, Dharanipragada K. Tamoxifen-induced hypertriglyceridemia causing acute pancreatitis. <i>J Pharmacol Pharmacother</i>. 2016;7(1):38‐40. doi:10.4103/0976-500X.179365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/27127396/pubmed" id="27127396" target="_blank">27127396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Soltamox.1">
<a name="Soltamox.1"></a>Soltamox (tamoxifen citrate) [prescribing information]. Raleigh, NC: Fortovia Therapeutics Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21119261">
<a name="21119261"></a>Srikantia N, Mukesh S, Krishnaswamy M. Crystalline maculopathy: a rare complication of tamoxifen therapy. <i>J Cancer Res Ther</i>. 2010;6(3):313‐315. doi:10.4103/0973-1482.73332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/21119261/pubmed" id="21119261" target="_blank">21119261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17509880">
<a name="17509880"></a>Srivastava A, Mansel RE, Arvind N, Prasad K, Dhar A, Chabra A. Evidence-based management of mastalgia: a meta-analysis of randomised trials. <i>Breast</i>. 2007;16(5):503-512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/17509880/pubmed" id="17509880" target="_blank">17509880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12480376">
<a name="12480376"></a>Stearns V, Ullmer L, López JF, Smith Y, Isaacs C, Hayes D. Hot flushes. <i>Lancet</i>. 2002;360(9348):1851‐1861. doi:10.1016/s0140-6736(02)11774-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/12480376/pubmed" id="12480376" target="_blank">12480376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15845599">
<a name="15845599"></a>Steiner AZ, Terplan M, and Paulson RJ, “Comparison of Tamoxifen and Clomifene Citrate for Ovulation Induction: A Meta-Analysis,” <i>Hum Reprod</i>, 2005, 20(6):1511-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/15845599/pubmed" id="15845599" target="_blank">15845599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11069218">
<a name="11069218"></a>Storen EC, Hay JE, Kaur J, Zahasky K, Hartmann L. Tamoxifen-induced submassive hepatic necrosis. <i>Cancer J</i>. 2000;6(2):58‐60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/11069218/pubmed" id="11069218" target="_blank">11069218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15741574">
<a name="15741574"></a>Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. <i>J Natl Cancer Inst</i>. 2005;97(5):375‐384. doi:10.1093/jnci/dji057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/15741574/pubmed" id="15741574" target="_blank">15741574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Tamoxifen Citrate [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9373465">
<a name="9373465"></a>Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. <i>Eye (Lond)</i>. 1997;11(pt 3):295‐297. doi:10.1038/eye.1997.64<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9373465/pubmed" id="9373465" target="_blank">9373465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22352823">
<a name="22352823"></a>Tarafdar S, Lim LT, Collins CE, Ramaesh K. Tamoxifen keratopathy as seen with in-vivo confocal microscopy. <i>Semin Ophthalmol</i>. 2012;27(1-2):27‐28. doi:10.3109/08820538.2011.631510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/22352823/pubmed" id="22352823" target="_blank">22352823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28882942">
<a name="28882942"></a>Temkar S, Pujari A, Agarwal D, Chawla R. Tamoxifen maculopathy in a male patient. <i>BMJ Case Rep</i>. 2017;2017:bcr2017222093. doi:10.1136/bcr-2017-222093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/28882942/pubmed" id="28882942" target="_blank">28882942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31157284">
<a name="31157284"></a>Tey TT, Maung AC, Lim KW, Hsiang JC. Acute pancreatitis caused by tamoxifen-induced severe hypertriglyceridemia after 4 years of tamoxifen use. <i>ACG Case Rep J</i>. 2019;6(2):1‐3. doi:10.14309/crj.0000000000000025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/31157284/pubmed" id="31157284" target="_blank">31157284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8963159">
<a name="8963159"></a>Therssen R, Jansen E, Leys A, Rutten J, Meyskens J. Screening for tamoxifen ocular toxicity: a prospective study. <i>Eur J Ophthalmol</i>. 1995;5(4):230‐234.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/8963159/pubmed" id="8963159" target="_blank">8963159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18243179">
<a name="18243179"></a>Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Consensus on Infertility Treatment Related to Polycystic Ovary Syndrome,” <i>Fertil Steril</i>, 2008, 89(3):505-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/18243179/pubmed" id="18243179" target="_blank">18243179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11208827">
<a name="11208827"></a>Thigpen T, Brady MF, Homesley HD, et al, “Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study,” <i>J Clin Oncol</i>, 2001, 19(2):364-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/11208827/pubmed" id="11208827" target="_blank">11208827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4061890">
<a name="4061890"></a>Török L. Treatment of oligozoospermia with tamoxifen (open and controlled studies). <i>Andrologia</i>. 1985;17(5):497-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/4061890/pubmed" id="4061890" target="_blank">4061890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24678744">
<a name="24678744"></a>Ugurlu S, Karagoz A, Altin Ekin M. Ocular findings in breast cancer patients using tamoxifen. <i>Cutan Ocul Toxicol</i>. 2015;34(1):16‐20. doi:10.3109/15569527.2014.888078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/24678744/pubmed" id="24678744" target="_blank">24678744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16446340">
<a name="16446340"></a>Vehmanen L, Elomaa I, Blomqvist C, et al, “Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status,” <i>J Clin Oncol</i>, 2006, 24(4):675-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/16446340/pubmed" id="16446340" target="_blank">16446340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23835710">
<a name="23835710"></a>Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2013;31(23):2942‐2962. doi:10.1200/JCO.2013.49.3122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/23835710/pubmed" id="23835710" target="_blank">23835710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26405621">
<a name="26405621"></a>Wang L, Miao H, Li X. Tamoxifen retinopathy: a case report. <i>Springerplus</i>. 2015;4:501. doi:10.1186/s40064-015-1258-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/26405621/pubmed" id="26405621" target="_blank">26405621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9149031">
<a name="9149031"></a>Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. <i>Cancer</i>. 1997;79(10):2024‐2027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/9149031/pubmed" id="9149031" target="_blank">9149031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27152880">
<a name="27152880"></a>Wibowo E, Pollock PA, Hollis N, Wassersug RJ. Tamoxifen in men: a review of adverse events. <i>Andrology</i>. 2016;4(5):776‐788. doi:10.1111/andr.12197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/27152880/pubmed" id="27152880" target="_blank">27152880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-323393">
<a name="323393"></a>Willis KJ, London DR, Bevis MA, Butt WR, Lynch SS, Holder G. Hormonal effects of tamoxifen in oligospermic men. <i>J Endocrinol</i>. 1977;73(1):171-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/323393/pubmed" id="323393" target="_blank">323393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16343223">
<a name="16343223"></a>Yildirim Y, Inal MM, Sanci M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. <i>Int J Gynecol Cancer</i>. 2005;15(6):1239‐1242. doi:10.1111/j.1525-1438.2005.00170.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/16343223/pubmed" id="16343223" target="_blank">16343223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25606038">
<a name="25606038"></a>Zafeiropoulos P, Nanos P, Tsigkoulis E, Stefaniotou M. Bilateral macular edema in a patient treated with tamoxifen: a case report and review of the literature. <i>Case Rep Ophthalmol</i>. 2014;5(3):451‐454. doi:10.1159/000370144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/25606038/pubmed" id="25606038" target="_blank">25606038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7929848">
<a name="7929848"></a>Zhang JJ, Jacob TJ, Valverde MA, et al. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. <i>J Clin Invest</i>. 1994;94(4):1690‐1697. doi:10.1172/JCI117514<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tamoxifen-pediatric-drug-information/abstract-text/7929848/pubmed" id="7929848" target="_blank">7929848</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 87811 Version 346.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
